Decreased plasma nesfatin-1 levels in patients with generalized anxiety disorder

Gunay, Hüseyin; Tutuncu, Recep; Aydın, Süleyman; Dağ, Ersel; Abaslı, Dilek

doi:10.1016/j.psyneuen.2012.04.007

Cited by 51 publications

(37 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In this study, we found no significant alteration in nesfatin-1 plasma concentrations between healthy controls and GAD patients, a finding which is contrary to a previous report by Gunay et al 17 , who reported decreased nesfatin-1 levels in GAD patients. The sample size in both studies was similar.…”

Section: Discussioncontrasting

confidence: 99%

“…Nesfatin-1 levels have been found to be altered in patients with depression 13 , panic disorder 14 , obsessive compulsive disorder 15 and suicide victims 16 . GAD patients have presented with significantly lower plasma levels of nesfatin-1 than controls 17 . Further confirmatory research on nesfatin-1 is required to clarify its pathophysiological role in psychiatric illnesses, including GAD.…”

Section: Introductionmentioning

confidence: 93%

See 1 more Smart Citation

Is There any Association Between Nesfatin-1 and Generalized Anxiety Disorder?

Bahçeci

Bağcıoğlu

Dilek

et al. 2014

Klinik Psikofarmakoloji Bülteni-Bulletin of Clinical Psychophar

View full text Add to dashboard Cite

Section: Discussioncontrasting

confidence: 99%

Section: Introductionmentioning

confidence: 93%

Is There any Association Between Nesfatin-1 and Generalized Anxiety Disorder?

Bahçeci

Bağcıoğlu

Dilek

et al. 2014

Klinik Psikofarmakoloji Bülteni-Bulletin of Clinical Psychophar

View full text Add to dashboard Cite

“…Our findings suggest that fat distribution is more important than weight gain or central obesity. Although expression of nesfatin-1 seems to depend on sex and nesfatin levels are higher in males [24][25][26] , we could not find any difference between the sexes. This issue also needs thorough investigation.…”

Section: Discussioncontrasting

confidence: 78%

Is There a Relationship between Obstructive Sleep Apnea Syndrome Severity and Nesfatin-1?

et al. 2015

View full text Add to dashboard Cite

Background: Obstructive sleep apnea syndrome (OSAS) and obesity frequently occur together. The relationship between increased appetite and obesity is well known; however, despite existing knowledge about the relationship between OSAS and obesity, it is not fully understood. Objectives: This study aimed to evaluate the relationship between OSAS and the appetite-suppressing hormone nesfatin-1 independent of body mass index (BMI). Methods: A total of 134 cases were included in the study; 102 with OSAS (OSAS group) and 32 healthy controls (control group). All cases underwent polysomnography, and nesfatin-1 levels were determined. Results: Nesfatin-1 levels were significantly lower in the OSAS group compared to the control group (3,776.5 ± 204.8 and 4,056.2 ± 101.5 pg/ml, respectively; p < 0.001). In addition, there was a statistically significant negative correlation between nesfatin-1 and the apnea hypopnea index (r = -0.543; p < 0.001). The statistically significant relationship persisted after adjusting for confounding intergroup factors such as age, gender and BMI (p < 0.001). In the OSAS group, there was a statistically significant correlation between nesfatin-1 and neck circumference (r = -0.304; p = 0.02) but not between nesfatin-1 and BMI and waist circumference. There was no statistically significant difference in nesfatin-1 levels between the sexes. Conclusion: OSAS patients have lower nesfatin-1 levels compared to controls, and a greater nesfatin-1 deficit corresponds to an increased severity of OSAS and an increased neck circumference. Replacement therapy may be a potential treatment for obese OSAS patients who have lower nesfatin-1 levels, which may have additional benefits through appetite suppression and weight loss.

show abstract

“…Nesfatin-1 is an 82-amino acid peptide that is involved in food restriction and in the regulation of homeostasis (13,15,39). Nesfatin-1 is localized in neurons of the hypothalamus and brain stem and is colocalized with stress-related substances such as CRF, oxytocin, proopiomelanocortin, NA, and 5-hydroxytryptamine (5-HT) (40).…”

Section: Discussionmentioning

confidence: 99%

“…Nesfatin produces three major peptide products such as nesfatin-1 (spanning residues 1-82), nesfatin-2 (residues 85-163), and named it NUCB2-encoded satiety and the fat-influencing protein as nesfatin (15). Nesfatin-1 is involved in the regulation of homeostasis and has anti-inflammatory, anti-apoptotic, and anti-ischemic properties (13,16,17).…”

Section: Introductionmentioning

confidence: 99%

Possible Activation of the Immune System by Chronic Peripheral Nesfatin-1 Application at the Acute Phase of Ischemia/Reperfusion Injury

Toru¹,

Ayada²,

Genç³

et al. 2015

Erciyes Med J

View full text Add to dashboard Cite

Objective: Organ transplantation is one of the clinical scenarios involving ischemia and reperfusion process. Ischemia/reperfusion is the pivotal mechanism of organ injury during transplantation. Thus, ischemia/reperfusion (I/R) injury is a biphasic phenomenon that can damage the graft by inflammatory responses. The hypothalamic-pituitary-adrenal (HPA) axis is the main hormonal system that is activated under the influence of stress. Normal HPA axis activity leading to the release of glucocorticoids is essential for homeostasis and survival during stress. Cortisol, a key controller of stress response, is released by the HPA axis.The disrupted release of cortisol in response to inflammation has been shown in animal models. Nesfatin-1 is a peptide involved in the regulation of homeostasis and has anti-inflammatory as well as anti-ischemic properties. Therefore, we aimed to identify the effect of chronic peripheral nesfatin-1 application on the plasma level of cortisol in a rat model of intestinal I/R-based stress.Materials and Methods: Two-month-old 28 Wistar Albino male rats that weighed an average of 200-250 g were used and were randomly divided into the following four experimental groups (n=7): laparotomy, I/R, nesfatin-1+laparotomy, nesfatin-1+I/R. Blood samples were collected in tubes with EDTA. Plasma cortisol levels were analyzed by rat enzyme-linked immunosorbent assay (ELISA) kits.Results: Statistically significant decrease was found in the plasma level of cortisol in nesfatin-1+I/R group compared with I/R group (p=0.026)Conclusion: Nesfatin-1 application can inhibit anti-inflammatory responses under the early phase of intestinal I/R and support immune reactions by reducing plasma cortisol level. This effect of nesfatin-1 may also increase the rejection of grafts during transplantation period.

show abstract

Decreased plasma nesfatin-1 levels in patients with generalized anxiety disorder

Cited by 51 publications

References 35 publications

Is There any Association Between Nesfatin-1 and Generalized Anxiety Disorder?

Is There any Association Between Nesfatin-1 and Generalized Anxiety Disorder?

Is There a Relationship between Obstructive Sleep Apnea Syndrome Severity and Nesfatin-1?

Possible Activation of the Immune System by Chronic Peripheral Nesfatin-1 Application at the Acute Phase of Ischemia/Reperfusion Injury

Contact Info

Product

Resources

About